Short Interest in Dyne Therapeutics, Inc. (NASDAQ:DYN) Grows By 6.9%

Dyne Therapeutics, Inc. (NASDAQ:DYN) saw a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 9,880,000 shares, a growth of 6.9% from the July 15th total of 9,240,000 shares. Based on an average daily volume of 1,260,000 shares, the days-to-cover ratio is currently 7.8 days.

Insider Activity at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 30,426 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $32.96, for a total transaction of $1,002,840.96. Following the transaction, the insider now directly owns 149,647 shares of the company’s stock, valued at $4,932,365.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Oxana Beskrovnaya sold 30,426 shares of Dyne Therapeutics stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $32.96, for a total transaction of $1,002,840.96. Following the sale, the insider now owns 149,647 shares of the company’s stock, valued at approximately $4,932,365.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Susanna Gatti High sold 10,163 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $35.33, for a total transaction of $359,058.79. Following the transaction, the chief operating officer now owns 148,792 shares in the company, valued at approximately $5,256,821.36. The disclosure for this sale can be found here. Insiders have sold a total of 194,102 shares of company stock worth $6,273,351 in the last 90 days. Company insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. bought a new stake in Dyne Therapeutics during the 1st quarter valued at approximately $140,666,000. Vanguard Group Inc. boosted its position in shares of Dyne Therapeutics by 47.7% during the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after acquiring an additional 1,110,629 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Dyne Therapeutics by 23,512.0% during the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after acquiring an additional 2,663,910 shares during the last quarter. Vivo Capital LLC grew its stake in Dyne Therapeutics by 58.0% during the first quarter. Vivo Capital LLC now owns 1,635,136 shares of the company’s stock valued at $46,422,000 after acquiring an additional 600,000 shares in the last quarter. Finally, Artal Group S.A. increased its holdings in Dyne Therapeutics by 24.6% in the 1st quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock valued at $43,095,000 after acquiring an additional 300,000 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on DYN shares. Jefferies Financial Group upped their price objective on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, May 20th. Oppenheimer reaffirmed an “outperform” rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research report on Monday, May 6th. Morgan Stanley boosted their target price on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday. JPMorgan Chase & Co. raised their price target on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. Finally, StockNews.com upgraded shares of Dyne Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $50.60.

Dyne Therapeutics Trading Down 0.8 %

NASDAQ DYN traded down $0.35 during trading hours on Friday, hitting $45.39. 819,904 shares of the company’s stock traded hands, compared to its average volume of 1,578,585. Dyne Therapeutics has a 52 week low of $6.40 and a 52 week high of $46.39. The firm has a market capitalization of $3.97 billion, a P/E ratio of -11.43 and a beta of 1.07. The business’s fifty day moving average price is $38.90 and its two-hundred day moving average price is $30.84.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. On average, sell-side analysts expect that Dyne Therapeutics will post -3 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.